Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Interact with Elvitegravir?
Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and Elvitegravir have a unknown drug interaction according to U.S. FDA drug labeling data. Elvitegravir is a modest inducer of CYP2C9 and may decrease the plasma concentrations of CYP2C9 substrates. 7.3 Potential for Other Drugs to Affect One or More Components of STRIBILD Elvitegravir and cobicistat, components of STRIBILD, are metabolized by CYP3A. Drugs that induce CYP3A activity are expected to increase the clearance of elvitegravir and cobicistat, resulting in decreased plasma concentration of cobicistat and elvitegravir, which may lead to loss of therapeutic effect of STRIBILD and development of resistance (Table 5). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Unknown
- Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Class
- Cytochrome P450 3A Inhibitor
- Management
- Consult your pharmacist
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and your doctor is considering prescribing Elvitegravir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider